Lentiviral particles allow easy gene delivery

Published: 19-Aug-2010
Manufacturing Analysis

Supplied ready to use

Lentiviral particles allow easy gene delivery
AMS Biotechnology’s (AMSBIO) expression-ready lentiviral particles allow easy gene delivery into hard-to-transfect cells including primary cells, non-dividing cells and cells in suspension.

The Abingdon, UK-based firm supplies the new particles ready to use, eliminating the need for any lipids or transfection reagents. The company says these pre-made lentiviral particles are proven to deliver genes in a highly reproducible and controllable manner for the expression of more than 250 human proteins, mouse proteins, enzymes and fluorescent markers.

Using proprietary protocols based on co-expressed red fluorescent protein by a 2A peptide processing (SureTitre) or RSV promoter (Inducible system), these lentiviral particles enable real time monitoring of protein expression.

All AMSBIO lentiviral products are said to be easy and safe to use by simply adding the high titre particles (1 x 107 IFU/ml or higher) to cultured cells, and you will be able to confirm the specific target's expression under a fluorescent microscope after 48–72 hours.

AMSBIO lentiviral particles are packaged in culture medium with 10% FBS, in serum-free medium or concentrated in PBS for in vivo use.

See more

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Read more
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. GLP-1 news round-up: what's happened in weight loss Lilly's retatrutide posts strong Phase III results, Novo Nordisk pays up to $2.6bn for an oral candidate and nasal and AI-designed approaches advance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II) Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Manufacturing
Why your coating process is less consistent than you think - and what to do about it

Why your coating process is less consistent than you think - and what to do about it

Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale
Subscribe now